Ginkgo Bioworks (DNA) Competitors $8.28 -0.08 (-0.93%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$7.96 -0.32 (-3.89%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. ANIP, JANX, APGE, KYMR, ARWR, IRON, TVTX, SDGR, IDYA, and MESOShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Disc Medicine (IRON), Travere Therapeutics (TVTX), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. ANI Pharmaceuticals Janux Therapeutics Apogee Therapeutics Kymera Therapeutics Arrowhead Pharmaceuticals Disc Medicine Travere Therapeutics Schrödinger IDEAYA Biosciences Mesoblast ANI Pharmaceuticals (NASDAQ:ANIP) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk. Which has higher valuation and earnings, ANIP or DNA? ANI Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$614.38M2.46$18.78M-$1.14-61.01Ginkgo Bioworks$227.04M2.12-$892.87M-$10.68-0.78 Is ANIP or DNA more profitable? ANI Pharmaceuticals has a net margin of -1.28% compared to Ginkgo Bioworks' net margin of -298.78%. ANI Pharmaceuticals' return on equity of 15.87% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.28% 15.87% 6.88% Ginkgo Bioworks -298.78%-58.54%-34.24% Do analysts rate ANIP or DNA? ANI Pharmaceuticals presently has a consensus price target of $79.75, indicating a potential upside of 14.67%. Ginkgo Bioworks has a consensus price target of $4.58, indicating a potential downside of 44.76%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe ANI Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60 Do insiders and institutionals have more ownership in ANIP or DNA? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, ANIP or DNA? ANI Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Does the MarketBeat Community believe in ANIP or DNA? ANI Pharmaceuticals received 416 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 64.42% of users gave ANI Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformANI PharmaceuticalsOutperform Votes44064.42% Underperform Votes24335.58% Ginkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Does the media refer more to ANIP or DNA? In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 4 mentions for Ginkgo Bioworks. ANI Pharmaceuticals' average media sentiment score of 0.93 beat Ginkgo Bioworks' score of 0.16 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryANI Pharmaceuticals beats Ginkgo Bioworks on 16 of the 19 factors compared between the two stocks. Remove Ads Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$480.64M$2.90B$5.33B$18.52BDividend YieldN/A1.91%5.11%4.22%P/E Ratio-0.6331.0021.7331.15Price / Sales2.12441.16379.2025.69Price / CashN/A168.6838.1517.53Price / Book0.383.476.464.29Net Income-$892.87M-$72.06M$3.20B$1.02B7 Day Performance21.62%3.17%2.86%-0.79%1 Month Performance18.40%-16.97%-8.55%-6.88%1 Year PerformanceN/A-29.07%10.47%1.74% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.5889 of 5 stars$8.28-0.9%$4.58-44.8%N/A$480.64M$227.04M-0.63640ANIPANI Pharmaceuticals3.6037 of 5 stars$66.77-1.1%$79.75+19.4%+4.9%$1.45B$614.38M-121.39600JANXJanux Therapeutics2.697 of 5 stars$24.49-5.0%$92.44+277.6%-44.0%$1.45B$10.59M-20.9430Positive NewsAPGEApogee Therapeutics2.1972 of 5 stars$32.24-0.3%$92.17+185.9%-38.1%$1.44BN/A-13.2591KYMRKymera Therapeutics1.4214 of 5 stars$21.91-0.7%$56.36+157.2%-26.0%$1.42B$47.07M-9.36170News CoveragePositive NewsGap DownARWRArrowhead Pharmaceuticals3.4061 of 5 stars$10.25-4.1%$41.44+304.5%-46.4%$1.40B$2.50M-1.98400Gap DownIRONDisc Medicine2.5627 of 5 stars$39.79-3.5%$93.80+135.8%+35.4%$1.38BN/A-10.0230Positive NewsGap DownHigh Trading VolumeTVTXTravere Therapeutics2.5531 of 5 stars$15.17+1.2%$31.46+107.4%+135.9%$1.34B$233.18M-3.69460Analyst ForecastSDGRSchrödinger2.3205 of 5 stars$18.25+1.2%$32.29+76.9%+0.2%$1.34B$207.54M-7.83790Insider TradeNews CoveragePositive NewsGap DownIDYAIDEAYA Biosciences3.4329 of 5 stars$15.15+3.0%$53.58+253.6%-59.1%$1.32B$7M-4.5880MESOMesoblast2.6518 of 5 stars$10.42-1.4%$18.00+72.8%+108.3%$1.32B$5.67M0.0080Positive News Remove Ads Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Janux Therapeutics Competitors Apogee Therapeutics Competitors Kymera Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Disc Medicine Competitors Travere Therapeutics Competitors Schrödinger Competitors IDEAYA Biosciences Competitors Mesoblast Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNA Stock Free DNA Stock Alerts